DBV Technologies (0QAJ) Receives a Buy From Kepler Capital
Kepler Capital Sticks to Their Buy Rating for DBV Technologies (0QAJ)
DBV Technologies Is Maintained at Buy by HC Wainwright & Co.
DBV Technologies Analyst Ratings
DBV Technologies Analyst Ratings
JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target
JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for DBV Technologies on Strong VITESSE Trial Progress and FDA Collaboration
Kepler Capital Sticks to Their Buy Rating for DBV Technologies (0QAJ)
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $5 Price Target
DBV Technologies Price Target Raised to $5.00/Share From $4.00 by JMP Securities
DBV Technologies Analyst Ratings
JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $5
JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Cuts Target Price to $5
JMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)
DBV Technologies Analyst Ratings
HC Wainwright & Co. Maintains Buy on DBV Technologies, Lowers Price Target to $5
Optimistic Buy Rating for DBV Technologies With Viaskin's Market Potential and Regulatory Prospects
Buy Rating Affirmed for DBV Technologies SA Amidst Strong Clinical Progress and Solid Financial Footing